Clinical Trial Update: Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD) [Phase 1, Phase 2]

View source ↗

Summary

The clinical trial evaluating the combination of azacitidine and avelumab in patients with acute myeloid leukemia and minimal residual disease has been withdraw…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• BAVENCIO (AVELUMAB)
• VIDAZA (AZACITIDINE)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Acute Myeloid Leukemia (AML), Minimal Residual Disease | Phase 1, Phase 2 | Status: WITHDRAWN